ApprovalTrail

Approval · Notice of Compliance 28625 · 2022

AG-FINASTERIDE: Notice of Compliance 28625

Issued July 21, 2022

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
28625
Date
July 21, 2022
Company
Angita Pharma Inc.Boucherville, Quebec, Canada
Product type
Prescription Pharmaceutical
Submission
Supplement to an Abbreviated New Drug Submission (SANDS), supplement
Submission class
Admin
Reason
Administrative: Labelling Update (to Match Licensor)
Canadian reference product
PROSCAR (Merck Frosst Canada Inc.)

Products in this notice

BrandDINStatus today
AG-FINASTERIDENot yet assigned—

Medicinal ingredients